TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17223857
Drug: Brivaracetam (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (600 mg)
Study: 17223857
Drug: Brivaracetam (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (150 mg) with high-fat meal
Study: 14707412
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g L-arginine infusion
Study: 11730275
Drug: Resting period
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resting period (R) after a protein meal (1.2 g/kg b.w. of protein)
Study: 11730275
Drug: Behavioural stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural stress period (S) after a protein meal (1.2 g/kg b.w. of protein)
Study: 1827271
Drug: Metoclopramide 4
Normalized name: metoclopramide 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 4 mg/kg as a single intravenous dose (regimen A)
Study: 1827271
Drug: Metoclopramide 3
Normalized name: metoclopramide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 3 mg/kg in two doses (regimen B)
Study: 1827271
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (single dose)
Study: 1827271
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (divided dose)
Study: 21084429
Drug: Crossover groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover groups (GD→C or CD→G)
Study: 16899425
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid esters (FAE's, Fumaderm) at a maximum dose of 120 mg dimethylfumarate per day for six months
Study: 16186995
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with 0.57 g/kg glutamine‐dipeptide
Study: 18620511
Drug: Chloroquine treatment
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine treatment (600 mg at day 1, 600 mg at days 2 and 3, 300 mg at days 4 and 5)
Study: 16094063
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg 0.125% bupivacaine with 1 microg/kg clonidine
Study: 16094063
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg 0.125% bupivacaine (controls)
Study: 12165122
Drug: Combined phototherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phototherapy and low-intensity laser therapy (LILT) with parameters: 532 mW; 5 kHz; 12 J/cm² for 4 weeks
Study: 12165122
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham treatments)
Study: 9933035
Drug: TUMT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUMT plus tamsulosin (0.4 mg daily)
Study: 7772590
Drug: Orthoptic exercises/treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthoptic exercises/treatment
Study: 2177647
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens 1.25 mg daily + dydrogesterone 20 mg daily for 12 days during months 2, 3, and 4, then 10 mg daily for the same duration in months 5, 6, and 7
Study: 2177647
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens 1.25 mg daily + dydrogesterone (two doses in reverse sequence)
Study: 2177647
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens 1.25 mg daily
Study: 6255535
Drug: Griseofulvin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (250 mg daily)
Study: 16570816
Drug: Intranasal Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal Budesonide (256 microg once daily intranasally for 8 weeks)
Study: 12808485
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of atorvastatin every other day
Study: 8632574
Drug: Luteinizing hormone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone‐releasing hormone agonist therapy for 12 weeks
Study: 1999793
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine with low-dose continuous morphine infusion (PCA-plus)
Study: 1999793
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered morphine
Study: 21642642
Drug: 0.7 ml
Normalized name: ethanol 0.7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 ml kg(‐1) ropivacaine
Study: 21642642
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml kg(‐1) ropivacaine
Study: 21642642
Drug: 1.3 ml
Normalized name: 1.3 ML Abilify 7.5 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 ml kg(‐1) ropivacaine
Study: 16934729
Drug: Deep transverse
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep transverse friction myotherapy (after two treatment sessions)
Study: 11737959
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A plus Fe supplementation (4800 retinol equivalent vitamin A, 120 mg Fe, and 500 microg folic acid)
Study: 11737959
Drug: Fe supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe supplementation alone (120 mg Fe and 500 microg folic acid)
Study: 9881325
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17 beta‐oestradiol daily on days 1‐28, combined with either 5 or 10 mg dydrogesterone on days 15‐28 for 12 months (13 cycles of 28 days)
Study: 7867285
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with plasma exchange and immune globulins
Study: 2522007
Drug: Nicardipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60 mg daily, for two months)
Study: 29262795
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 900 mg once daily for six months
Study: 29262795
Drug: Placebo (similar-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar-looking placebo tablets)
Study: 21956102
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone replacement therapy (no HRT)
Study: 18471588
Drug: Hand-held computer
Normalized name: PRECISION Q-I-D SENSOR,HAND HELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand-held computer (PDA) intervention with daily feedback and goal-setting
Study: 7672138
Drug: Octreotide (long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (long‐acting somatostatin analogue) administered SC for 6 weeks
Study: 7412158
Drug: Methazolamide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (oral doses)
Study: 7412158
Drug: Acetazolamide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (oral medication)
Study: 30338823
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (3-4 courses of cisplatin, ifosfamide, and adriamycin)
Study: 24280811
Drug: Palonosetron-dexamethasone combination
Normalized name: palonosetron, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron-dexamethasone combination (0.075 mg palonosetron and 8 mg dexamethasone)
Study: 22710099
Drug: Diet supplementation
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplementation with olive leaves (10 g/kg)
Study: 22710099
Drug: Diet supplementation
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplementation with α‐tocopheryl acetate (200 mg/kg)
Study: 2206836
Drug: diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac gel (Voltarol Emulgel) 4 g tds
Study: 2206836
Drug: felbinac gel
Normalized name: felbinac
DrugBank: Felbinac (DB07477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: felbinac gel (Traxam) 4 g tds
Study: 6108335
Drug: Ketazolam (once-daily)
DrugBank: Ketazolam (DB01587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketazolam (once-daily)
Study: 6108335
Drug: Ketazolam (three-times-daily)
Normalized name: bupropion
DrugBank: Ketazolam (DB01587)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketazolam (three-times-daily)
Study: 23049924
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate treatment
Study: 23049924
Drug: Folinate rescue
Normalized name: Folixate
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folinate rescue therapy
Study: 16988651
Drug: Arabinoxylan (AX)
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arabinoxylan (AX) supplement 15 g
Study: 16269401
Drug: ASA 150
Normalized name: ASA 150 MG Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 150 mg daily and Low Molecular Weight Heparin (LMWH) 5000 IU x2 for three days
Study: 16269401
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (ASA) 150 mg daily
Study: 14675849
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug treatment
Study: 10520100
Drug: Subcutaneous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous patient‐controlled analgesia (PCA) (bolus dose 2.5 mg diamorphine in 1 ml with a 20‐minute lockout)
Study: 10520100
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia (PCA) (bolus dose 0.5 mg diamorphine in 1 ml with a 5‐minute lockout)
Study: 23248037
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) add-on therapy
Study: 18087553
Drug: Enalapril 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10.0 mg/d
Study: 18087553
Drug: Enalapril 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10.0 mg + Folic acid 0.4 mg/d
Study: 18087553
Drug: Enalapril 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10.0 mg + Folic acid 0.8 mg/d
Study: 15824681
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (HDE) 0.1 mg/kg for initial dose and 0.2 mg/kg for subsequent doses
Study: 15824681
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (SDE) 0.01 mg/kg
Study: 7990367
Drug: Microwave resonance
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave resonance treatment (MRT)
Study: 16160626
Drug: Paroxetine (PAR)
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (PAR) up to 40 mg daily
Study: 16160626
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (VEN-XR) up to 225 mg daily
Study: 8314541
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy and radiotherapy
Study: 3303886
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg every 6 hours)
Study: 31558624
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily oral sustained-release morphine
Study: 29995672
Drug: Histamine H2
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2 receptor blockers (H2RBs)
Study: 1748229
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + dipyridamole (225 mg/day)
Study: 6847332
Drug: Drug counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug counseling alone
Study: 23464577
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin desensitization (100 mg daily)
Study: 19918203
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg daily for 12 months)
Study: 18976766
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drugs for 12 months)
Study: 15152709
Drug: Peer Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer Group Therapy
Study: 7942049
Drug: Alpha-tocopherol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (400 I.U. d‐1) and ascorbic acid (200 mg d‐1) supplementation
Study: 3263876
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg daily
Study: 3263876
Drug: Fluoxetine 60-80
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60-80 mg daily
Study: 3263876
Drug: Amitriptyline 100
Normalized name: amitriptyline 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 100 mg daily
Study: 3263876
Drug: Amitriptyline 150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150-200 mg daily
Study: 31797437
Drug: Surgical excision,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical excision, carbon dioxide (CO2) laser therapy, and triamcinolone acetonide (TAC) intralesional injections during surgery and follow-up.
Study: 21486976
Drug: IM20 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM20 × 3 (standard dose, 20 μg)
Study: 21486976
Drug: IM40 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM40 × 4 (double doses, 40 μg)
Study: 21486976
Drug: ID4 ×
Normalized name: Idarubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID4 × 4 (low doses, 4 μg)
Study: 18392831
Drug: Ultravist 300
Normalized name: Ultravist 300mg I/ml Solution for Injection
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultravist 300 (300 mg iodine/ml) at a flow rate of 4.9 ml/s, 148 ml
Study: 18392831
Drug: Ultravist 370
Normalized name: Ultravist 370mg I/ml Solution for Injection
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultravist 370 (370 mg iodine/ml) at a flow rate of 4.0 ml/s, 120 ml
Study: 12931764
Drug: Toothbrush B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothbrush B (Braun Oral B) activated
Study: 8511445
Drug: Placebo-controlled vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled vaccine
Study: 18035098
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 160 mg daily for 26 weeks
Study: 16186437
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with aspirin
Study: 16186437
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus colchicine 1.0 to 2.0 mg for the first day and then 0.5 to 1.0 mg/d for 3 months
Study: 11715489
Drug: GLN group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLN group (glutamine dipeptide enriched enteral nutrition at 0.5 g.kg‐1.day‐1)
Study: 2316233
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide gel (30 mL) with quinidine gluconate (648 mg)
Study: 2316233
Drug: Quinidine gluconate
Normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine gluconate (648 mg) without aluminum hydroxide gel
Study: 30630371
Drug: Captopril +
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril + Metformin
Study: 29960288
Drug: Tiaoshen Kaiqiao
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaoshen Kaiqiao acupuncture therapy and placebo starch tablets treatment
Study: 29960288
Drug: Fluoxetine tablets
Normalized name: Fluoxetine Tablets
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine tablets and body acupuncture treatment
Study: 29960288
Drug: Tiaoshen Kaiqiao
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaoshen Kaiqiao acupuncture therapy
Study: 25466703
Drug: Nicotine (6‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (6‐mg gum) + MAO‐A inhibition (moclobemide 75 mg)
Study: 25466703
Drug: Nicotine (6‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (6‐mg gum)
Study: 7871062
Drug: Melatonin 20
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 20 mg
Study: 11464450
Drug: Eprosartan (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (400-800 mg) alone or in combination with hydrochlorothiazide (HCTZ)
Study: 29095245
Drug: Intra-articular Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Steroid (IAS) injection
Study: 28783858
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine group (n=48)
Study: 26355928
Drug: Sulodexide (Vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (Vessel Due F) treatment for 50 days
Study: 26355928
Drug: Sulodexide (Vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (Vessel Due F) treatment
Study: 21128816
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) plus Levothyroxine (L‐T₄)
Study: 21128816
Drug: Levothyroxine (L‐T₄)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L‐T₄)
Study: 17641893
Drug: Capecitabine 628
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 628 mg/m² b.i.d. plus paclitaxel 80 mg/m²
Study: 17641893
Drug: Capecitabine 829
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 829 mg/m² b.i.d. plus paclitaxel 80 mg/m²
Study: 15746509
Drug: Nonpharmacologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapies
Study: 15746509
Drug: Pharmacologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapies
Study: 12911181
Drug: High-dose albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose albuterol (HDA)
Study: 8546472
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (400 mg UFT therapy daily for 10 days)
Study: 2070704
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC (three tablets four times daily)
Study: 31393353
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy with cognitive-behavioral therapy (MTCBP) for 12 weeks
Study: 31393353
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy with cognitive-behavioral therapy (MTCBP)
Study: 30334434
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral probiotics, dosage and duration not specified
Study: 27736051
Drug: N-Acetylcysteine (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetylcysteine (2,400 mg/d)
Study: 27736051
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cognitive-behavioral therapy for SUD
Study: 20642198
Drug: Self-management education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management education (contract to adopt behavior, workbook, weekly reinforcements for 12 weeks, frequent follow-up visits)
Study: 17661935
Drug: HA gel
Normalized name: Neevo DHA Gelcap
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA gel
Study: 17661935
Drug: hylan B
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan B plus gel
Study: 10718074
Drug: Control +
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control + caffeine (Cc)
Study: 9196163
Drug: ACTH 2
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 2 mg plus 1 mg on day 4
Study: 9196163
Drug: ACTH 1
Normalized name: adrenocorticotropin (ACTH 1-18),I-125 (TYR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 1 mg
Study: 1546123
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 mg/day, reduced to 300 mg/day after 4 weeks if required)
Study: 1546123
Drug: Amineptine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine (200 mg/day, reduced to 100 mg/day after 4 weeks if required)
Study: 2864663
Drug: Intensive antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antacid and thrombin
Study: 26289613
Drug: eHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth intervention (monthly teleassistance)
Study: 15927063
Drug: Single inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single inhalation of hyaluronic acid
Study: 10340882
Drug: Breast-Conservation Therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-Conservation Therapy (BCT)
Study: 7488812
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for 6 months (protocol C)